BioXcel Therapeutics Inc. (NASDAQ:BTAI) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET
Company Participants
Vimal Mehta - Chief Executive Officer
Matt Wiley - Chief Commercial Officer
Richard Steinhart - Vice President, Chief Financial Officer
Rob Risinger - Chief Medical Officer, Neuroscience
Conference Call Participants
Greg Harrison - Bank of America
Robyn Karnauskas - Truist Securities
Sumant Kulkarni - Canaccord
Yatin Suneja - Guggenheim Partners
Colin Bristow - UBS
Corinne Jenkins - Goldman Sachs
Anita Dushyanth - Berenberg
Operator
Good morning and welcome to the BioXcel Therapeutics first quarter 2022 financial results conference call. At this time, all participants are in a listen-only mode. If during the conference you require operator assistance, please press star, zero on your telephone keypad. After the presentation, there will be a question and answer session. If you would like to register a question, you may press star, one on your telephone keypad.
Just to remind everyone, certain matters discussed in today’s conference call and/or answers that may be given to questions asked are forward-looking statements subject to risks and uncertainties related to future events and/or the future financial performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements. Risk factors that may affect results are detailed in the company’s most recent public filings with the U.S. Securities and Exchange Commission, including BioXcel’s annual report on Form 10-K for the year ended December 31, 2021 which can be found at www.BioXceltherapeutics.com or on www.sec.gov, which will be update in its quarterly report on Form 10-Q for the quarter ended March 31, 2022.
As a reminder, today’s conference is being recorded.
Joining us on today’s call are Dr. Vimal Mehta, Chief Executive Officer; Richard Steinhart, Chief Financial Officer; Matt Wiley, Chief Commercial Officer; Dr. Rob Risinger, Chief Medical Officer of Neuroscience; Dr. Frank Yocca, Chief Scientific Officer; and Dr. Vince O’Neill, Chief Medical Officer of Oncology.
It is now my pleasure to turn the call over to Dr. Mehta, the CEO of BioXcel Therapeutics. Please go ahead.
Vimal Mehta
Thank you Operator. Welcome everyone and thank you for joining our call today to discuss BioXcel’s financial performance and business highlights for the first quarter of 2022.
As you know, BioXcel Therapeutics is a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immune-oncology. It has been an already transformational year for the company highlighted by our first FDA approval of IGALMI, our orally dissolving sublingual film approved last month for the acute treatment of mild, moderate or severe agitation associated with schizophrenia or Bipolar I or II disorders in adults. We are gearing up for commercial launch to deliver this new treatment option to patients and caregivers. Our team has made tremendous progress preparing for the deployment of our U.S. national sales force and have finalized pricing for broad market access. Our Chief Commercial Officer, Matt Wiley will discuss key commercial activities in more detail shortly.